Medical - Diagnostics & Research
Compare Stocks
5 / 10Stock Comparison
RDNT vs UHS vs HCA vs THC vs USPH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
RDNT vs UHS vs HCA vs THC vs USPH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $4.45B | $10.68B | $95.95B | $17.01B | $897M |
| Revenue (TTM) | $2.04B | $17.76B | $75.60B | $21.45B | $695M |
| Net Income (TTM) | $47M | $1.52B | $6.78B | $1.70B | $11M |
| Gross Margin | 11.2% | 67.6% | 41.5% | 42.8% | 22.0% |
| Operating Margin | 3.0% | 11.5% | 15.8% | 16.1% | 12.2% |
| Forward P/E | 91.8x | 7.3x | 14.2x | 10.9x | 20.6x |
| Total Debt | $1.86B | $5.51B | $50.20B | $13.17B | $426M |
| Cash & Equiv. | $767M | $138M | $1.04B | $2.88B | $36M |
RDNT vs UHS vs HCA vs THC vs USPH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| RadNet, Inc. (RDNT) | 100 | 337.4 | +237.4% |
| Universal Health Se… (UHS) | 100 | 161.7 | +61.7% |
| HCA Healthcare, Inc. (HCA) | 100 | 401.5 | +301.5% |
| Tenet Healthcare Co… (THC) | 100 | 892.1 | +792.1% |
| U.S. Physical Thera… (USPH) | 100 | 79.6 | -20.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RDNT vs UHS vs HCA vs THC vs USPH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RDNT is the clearest fit if your priority is long-term compounding.
- 9.5% 10Y total return vs THC's 5.2%
UHS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.60, Low D/E 74.3%, current ratio 1.05x
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Beta 0.29, yield 0.7%, current ratio 0.83x
- 9.0% margin vs USPH's 1.5%
- Beta 0.29 vs RDNT's 1.43
THC is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.33 vs HCA's 0.67
- Lower P/E (10.9x vs 20.6x)
- +27.4% vs USPH's -14.3%
USPH ranks third and is worth considering specifically for growth exposure.
- Rev growth 16.3%, EPS growth -22.8%, 3Y rev CAGR 12.2%
- 16.3% revenue growth vs THC's 3.1%
- 3.1% yield, 5-year raise streak, vs HCA's 0.7%, (2 stocks pay no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs THC's 3.1% | |
| Value | Lower P/E (10.9x vs 20.6x) | |
| Quality / Margins | 9.0% margin vs USPH's 1.5% | |
| Stability / Safety | Beta 0.29 vs RDNT's 1.43 | |
| Dividends | 3.1% yield, 5-year raise streak, vs HCA's 0.7%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +27.4% vs USPH's -14.3% | |
| Efficiency (ROA) | 11.3% ROA vs USPH's 0.9%, ROIC 19.9% vs 5.6% |
RDNT vs UHS vs HCA vs THC vs USPH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RDNT vs UHS vs HCA vs THC vs USPH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
THC leads in 2 of 6 categories
UHS leads 1 • USPH leads 1 • RDNT leads 0 • HCA leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
THC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 108.7x USPH's $695M. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to USPH's 1.5%. On growth, RDNT holds the edge at +14.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.0B | $17.8B | $75.6B | $21.5B | $695M |
| EBITDAEarnings before interest/tax | $214M | $2.7B | $15.5B | $4.3B | $107M |
| Net IncomeAfter-tax profit | $47M | $1.5B | $6.8B | $1.7B | $11M |
| Free Cash FlowCash after capex | -$178M | $894M | $7.7B | $3.3B | $67M |
| Gross MarginGross profit ÷ Revenue | +11.2% | +67.6% | +41.5% | +42.8% | +22.0% |
| Operating MarginEBIT ÷ Revenue | +3.0% | +11.5% | +15.8% | +16.1% | +12.2% |
| Net MarginNet income ÷ Revenue | +2.3% | +8.6% | +9.0% | +7.9% | +1.5% |
| FCF MarginFCF ÷ Revenue | -8.7% | +5.0% | +10.2% | +15.6% | +9.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.8% | +9.6% | +6.7% | +2.8% | +7.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -114.1% | +17.7% | +44.6% | +87.6% | -115.0% |
Valuation Metrics
UHS leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 7.4x trailing earnings, UHS trades at a 82% valuation discount to USPH's 41.5x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $4.5B | $10.7B | $95.9B | $17.0B | $897M |
| Enterprise ValueMkt cap + debt − cash | $5.5B | $16.0B | $145.1B | $27.3B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -230.00x | 7.38x | 15.12x | 12.53x | 41.55x |
| Forward P/EPrice ÷ next-FY EPS est. | 91.75x | 7.30x | 14.19x | 10.94x | 20.63x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.46x | 0.72x | 0.38x | — |
| EV / EBITDAEnterprise value multiple | 25.88x | 6.14x | 9.37x | 6.34x | 12.52x |
| Price / SalesMarket cap ÷ Revenue | 2.18x | 0.61x | 1.27x | 0.80x | 1.15x |
| Price / BookPrice ÷ Book value/share | 3.19x | 1.48x | — | 1.97x | 1.16x |
| Price / FCFMarket cap ÷ FCF | 52.01x | 12.57x | 12.47x | 6.72x | 14.71x |
Profitability & Efficiency
Evenly matched — HCA and USPH each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $1 for USPH. USPH carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs USPH's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.8% | +20.7% | — | +19.6% | +1.4% |
| ROA (TTM)Return on assets | +1.3% | +9.8% | +11.3% | +5.7% | +0.9% |
| ROICReturn on invested capital | +2.0% | +12.3% | +19.9% | +13.2% | +5.6% |
| ROCEReturn on capital employed | +2.1% | +16.0% | +27.0% | +13.8% | +7.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 7 | 7 | 5 |
| Debt / EquityFinancial leverage | 1.37x | 0.74x | — | 1.47x | 0.55x |
| Net DebtTotal debt minus cash | $1.1B | $5.4B | $49.2B | $10.3B | $390M |
| Cash & Equiv.Liquid assets | $767M | $138M | $1.0B | $2.9B | $36M |
| Total DebtShort + long-term debt | $1.9B | $5.5B | $50.2B | $13.2B | $426M |
| Interest CoverageEBIT ÷ Interest expense | 1.46x | 10.92x | 5.37x | 4.28x | 15.42x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $5,664 for USPH. Over the past 12 months, THC leads with a +27.4% total return vs USPH's -14.3%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs USPH's -17.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -19.0% | -22.3% | -8.6% | -2.7% | -24.6% |
| 1-Year ReturnPast 12 months | +4.6% | -8.2% | +19.7% | +27.4% | -14.3% |
| 3-Year ReturnCumulative with dividends | +100.0% | +20.8% | +57.4% | +178.5% | -43.7% |
| 5-Year ReturnCumulative with dividends | +147.1% | +12.5% | +109.7% | +190.4% | -43.4% |
| 10-Year ReturnCumulative with dividends | +947.4% | +30.8% | +450.5% | +523.4% | +22.6% |
| CAGR (3Y)Annualised 3-year return | +26.0% | +6.5% | +16.3% | +40.7% | -17.4% |
Risk & Volatility
Evenly matched — HCA and THC each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than RDNT's 1.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. THC currently trades 78.5% from its 52-week high vs USPH's 63.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.43x | 0.60x | 0.29x | 0.71x | 0.93x |
| 52-Week HighHighest price in past year | $85.84 | $246.33 | $556.52 | $247.21 | $93.50 |
| 52-Week LowLowest price in past year | $50.76 | $152.33 | $330.00 | $146.60 | $58.55 |
| % of 52W HighCurrent price vs 52-week peak | +67.0% | +69.2% | +77.1% | +78.5% | +63.1% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 39.7 | 30.8 | 52.9 | 46.1 |
| Avg Volume (50D)Average daily shares traded | 822K | 793K | 1000K | 1.2M | 171K |
Analyst Outlook
USPH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: RDNT as "Buy", UHS as "Hold", HCA as "Buy", THC as "Buy", USPH as "Buy". Consensus price targets imply 72.9% upside for USPH (target: $102) vs 22.9% for HCA (target: $527). For income investors, USPH offers the higher dividend yield at 3.06% vs UHS's 0.47%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $92.00 | $231.50 | $527.45 | $268.00 | $102.00 |
| # AnalystsCovering analysts | 11 | 43 | 46 | 32 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | +0.7% | — | +3.1% |
| Dividend StreakConsecutive years of raises | 0 | 1 | 5 | 0 | 5 |
| Dividend / ShareAnnual DPS | — | $0.80 | $2.94 | — | $1.80 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +9.1% | +10.5% | +8.4% | +0.6% |
THC leads in 2 of 6 categories (Income & Cash Flow, Total Returns). UHS leads in 1 (Valuation Metrics). 2 tied.
RDNT vs UHS vs HCA vs THC vs USPH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RDNT or UHS or HCA or THC or USPH a better buy right now?
For growth investors, U.
S. Physical Therapy, Inc. (USPH) is the stronger pick with 16. 3% revenue growth year-over-year, versus 3. 1% for Tenet Healthcare Corporation (THC). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate RadNet, Inc. (RDNT) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RDNT or UHS or HCA or THC or USPH?
On trailing P/E, Universal Health Services, Inc.
(UHS) is the cheapest at 7. 4x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — RDNT or UHS or HCA or THC or USPH?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -43. 4% for U. S. Physical Therapy, Inc. (USPH). Over 10 years, the gap is even starker: RDNT returned +947. 4% versus USPH's +22. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RDNT or UHS or HCA or THC or USPH?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus RadNet, Inc. 's 1. 43β — meaning RDNT is approximately 398% more volatile than HCA relative to the S&P 500. On balance sheet safety, U. S. Physical Therapy, Inc. (USPH) carries a lower debt/equity ratio of 55% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — RDNT or UHS or HCA or THC or USPH?
By revenue growth (latest reported year), U.
S. Physical Therapy, Inc. (USPH) is pulling ahead at 16. 3% versus 3. 1% for Tenet Healthcare Corporation (THC). On earnings-per-share growth, the picture is similar: Universal Health Services, Inc. grew EPS 37. 3% year-over-year, compared to -768. 4% for RadNet, Inc.. Over a 3-year CAGR, RDNT leads at 12. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RDNT or UHS or HCA or THC or USPH?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus 1. 9% for U. S. Physical Therapy, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus 3. 0% for RDNT. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RDNT or UHS or HCA or THC or USPH more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 91. 8x for RadNet, Inc. — 84. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USPH: 72. 9% to $102. 00.
08Which pays a better dividend — RDNT or UHS or HCA or THC or USPH?
In this comparison, USPH (3.
1% yield), HCA (0. 7% yield), UHS (0. 5% yield) pay a dividend. RDNT, THC do not pay a meaningful dividend and should not be held primarily for income.
09Is RDNT or UHS or HCA or THC or USPH better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, RDNT: +947. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RDNT and UHS and HCA and THC and USPH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RDNT is a small-cap quality compounder stock; UHS is a mid-cap deep-value stock; HCA is a mid-cap deep-value stock; THC is a mid-cap deep-value stock; USPH is a small-cap high-growth stock. HCA, USPH pay a dividend while RDNT, UHS, THC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.